Chief Accounting Officer
Niagen Bioscience, Inc. (NAGE)Equibles does not estimate personal net worth.
Get an email with a short summary when Niagen Bioscience, Inc. publishes a filing, an earnings call transcript or a press release.
Get NAGE alertsOzan Pamir is recorded as Chief Accounting Officer at Niagen Bioscience, Inc. (NAGE) since October 21, 2024 and CFO at Niagen Bioscience, Inc. (NAGE). The newest filing on record that lists Ozan Pamir as CFO at Niagen Bioscience, Inc. (NAGE) is dated April 29, 2026. Niagen Bioscience, Inc. reported in an 8-K filed September 20, 2024 that Ozan Pamir was appointed Chief Financial Officer and Principal Accounting Officer, effective October 21, 2024. The proxy statement of Niagen Bioscience, Inc. reports total compensation of $461,641 for Ozan Pamir in fiscal 2024, including a base salary of $69,231. Ozan Pamir has spoken on 6 earnings calls across 1 company, most recently for Niagen Bioscience, Inc. on August 4, 2026. Niagen Bioscience, Inc. is classified in the Packaged Foods industry within the Consumer Defensive sector. Other leadership on record at Niagen Bioscience, Inc. includes Robert Fried (CEO and Board Member), Frank Jaksch (Chairman and Board Member), James Lee (CFO and Chief Accounting Officer) and 7 others.
“On September 19, 2024, the Board of Directors (the "Board") of ChromaDex Corporation (the "Company" or "ChromaDex") appointed Ozan Pamir as the Company's Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024 (the "Effective Date").”
“So the Priority Review Voucher is a program that's dedicated for rare pediatric diseases and orphan drugs. Once you receive those designations and you receive approval by the FDA for that drug, there's no reason for the company to not receive that voucher.”
“It is a pleasure to once again address our investors, partners, and team members today. We had a solid start to the year with strong e-commerce growth coupled with exceptional net income.”
“Thank you, Andrew, and thank you to our investors, partners, and team members for joining us today. It is a pleasure to speak with you and to present yet another quarter of outstanding results.”
“Thanks Rob and thank you to our investors, partners, and team members for joining us today. I want to echo Rob's sentiment that the company's performance in the first half of this year has been exceptional and is attributable to our consistent focus, dedication, and discipline.”
“It is a pleasure to speak to our investors, partners, and employees who are here with us today. Having joined Chromadex just a few months ago, I've been deeply impressed by the team's dedication and the clear vision driving this company forward.”
2024-10-21–present
Start not stated–present
Last confirmed April 29, 2026
Packaged Foods · Consumer Defensive
CFO, Chief Accounting Officer
2024-10-21–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Niagen Bioscience, Inc. (NAGE) | Chief Financial Officer | $69,231 | $461,641 |
